fbpx

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

All things MYC from the lab to the clinic: latest insights, ‘omycs’, tips & tricks

18/06/2021|Comments Off on All things MYC from the lab to the clinic: latest insights, ‘omycs’, tips & tricks

  • Dr. Elena Garralda

VHIO’s Elena Garralda: Author of ESMO’s Perspectives On target column

15/06/2021|Comments Off on VHIO’s Elena Garralda: Author of ESMO’s Perspectives On target column

SOLTI basket trial set to simultaneously evaluate the efficacy of immune-based therapy across multiple cancer types in patients with PD1-high mRNA expressing tumors

14/06/2021|Comments Off on SOLTI basket trial set to simultaneously evaluate the efficacy of immune-based therapy across multiple cancer types in patients with PD1-high mRNA expressing tumors

ASCO Oral: Phase III COSMIC-311 promises a new standard of care for patients with previously treated differentiated thyroid cancer

07/06/2021|Comments Off on ASCO Oral: Phase III COSMIC-311 promises a new standard of care for patients with previously treated differentiated thyroid cancer

ASCO Oral: Landmark study rings in the first immune-based therapy for patients with resected, high-risk early-stage non-small cell lung cancer

07/06/2021|Comments Off on ASCO Oral: Landmark study rings in the first immune-based therapy for patients with resected, high-risk early-stage non-small cell lung cancer

ASCO Plenary: PARPi prevents disease recurrence in BRCA-mutated high-risk, early stage breast cancer

03/06/2021|Comments Off on ASCO Plenary: PARPi prevents disease recurrence in BRCA-mutated high-risk, early stage breast cancer

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2020

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS